CoLucid appoints Thomas Mathers CEO
This article was originally published in Scrip
CoLucid Pharmaceuticals, a privately held biopharmaceutical company, has appointed Thomas Mathers chief executive officer, succeeding Dr James White who will become CoLucid's scientific director. Mr Mathers previously served as chairman and CEO of Peptimmune, and is currently chairman of Declion Pharmaceuticals and a board member of the Biotechnology Industry Organization.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.